JP2024534499A - Il5ra細胞表面マーカー - Google Patents
Il5ra細胞表面マーカー Download PDFInfo
- Publication number
- JP2024534499A JP2024534499A JP2024517427A JP2024517427A JP2024534499A JP 2024534499 A JP2024534499 A JP 2024534499A JP 2024517427 A JP2024517427 A JP 2024517427A JP 2024517427 A JP2024517427 A JP 2024517427A JP 2024534499 A JP2024534499 A JP 2024534499A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- recombinant polypeptide
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4214—Receptors for cytokines
- A61K40/4217—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163247239P | 2021-09-22 | 2021-09-22 | |
| US63/247,239 | 2021-09-22 | ||
| PCT/US2022/076862 WO2023049803A1 (en) | 2021-09-22 | 2022-09-22 | Il5ra cell surface markers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024534499A true JP2024534499A (ja) | 2024-09-20 |
| JP2024534499A5 JP2024534499A5 (cg-RX-API-DMAC7.html) | 2025-09-30 |
Family
ID=85721256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024517427A Pending JP2024534499A (ja) | 2021-09-22 | 2022-09-22 | Il5ra細胞表面マーカー |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240417443A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4405383A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024534499A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240069766A (cg-RX-API-DMAC7.html) |
| CN (2) | CN118251407A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022349077A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3232203A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024003250A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023049803A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121538180A (zh) * | 2025-11-28 | 2026-02-17 | 中国医学科学院肿瘤医院 | 经修饰的单核细胞、其制备方法和应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003533998A (ja) * | 2000-05-22 | 2003-11-18 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー | レセプターを用いた相互作用の捕捉法 |
| JP2020527937A (ja) * | 2017-06-07 | 2020-09-17 | プレシゲン,インコーポレイテッド | 新規の細胞タグの発現 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5453491A (en) * | 1990-09-11 | 1995-09-26 | Kiyoshi Takatsu | Murine interleukin-5 receptor |
| PT3072525T (pt) * | 2007-05-14 | 2018-04-20 | Astrazeneca Ab | Métodos para reduzir os níveis de basófilos |
| ES3053874T3 (en) * | 2015-08-24 | 2026-01-27 | Glaxosmithkline Ip No 2 Ltd | Biopharmaceutical compositions |
| HK1255922A1 (zh) * | 2015-11-04 | 2019-09-06 | Astrazeneca Ab | 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子 |
| IL296242A (en) * | 2020-03-10 | 2022-11-01 | Massachusetts Inst Technology | Methods for generating engineered memory-like nk cells and compositions thereof |
-
2022
- 2022-09-22 WO PCT/US2022/076862 patent/WO2023049803A1/en not_active Ceased
- 2022-09-22 CN CN202280074739.XA patent/CN118251407A/zh active Pending
- 2022-09-22 EP EP22873860.5A patent/EP4405383A4/en active Pending
- 2022-09-22 AU AU2022349077A patent/AU2022349077A1/en active Pending
- 2022-09-22 KR KR1020247012657A patent/KR20240069766A/ko active Pending
- 2022-09-22 US US18/693,418 patent/US20240417443A1/en active Pending
- 2022-09-22 CA CA3232203A patent/CA3232203A1/en active Pending
- 2022-09-22 MX MX2024003250A patent/MX2024003250A/es unknown
- 2022-09-22 CN CN202411599318.6A patent/CN119661725A/zh active Pending
- 2022-09-22 JP JP2024517427A patent/JP2024534499A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003533998A (ja) * | 2000-05-22 | 2003-11-18 | フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー | レセプターを用いた相互作用の捕捉法 |
| JP2020527937A (ja) * | 2017-06-07 | 2020-09-17 | プレシゲン,インコーポレイテッド | 新規の細胞タグの発現 |
Non-Patent Citations (8)
| Title |
|---|
| "Interleukin-5 receptor subunit alpha", UNIPROTKB/SWISS-PROT[ONLINE],[検索日 2026.06.19], RETRIEVED FROM THE INTERNET, JPN6026027145, 2 June 2021 (2021-06-02), ISSN: 0005895038 * |
| BLOOD, vol. Vol. 118,No. 5,p.1255-1263, JPN6026027149, 2011, ISSN: 0005895042 * |
| EUROPEAN JOURNAL OF IMMUNOLOGY, vol. Vol. 25,No. 7,p.1857-1864, JPN6026027142, 1995, ISSN: 0005895035 * |
| FRONTIERS IN ENDOCRINOLOGY, vol. Vol. 8,Article 71, JPN6026027146, 18 April 2017 (2017-04-18), ISSN: 0005895039 * |
| JOURNAL OF BIOLOGICAL CHEMISTRY, vol. Vol. 279,No. 10,p.9547-9556, JPN6026027147, 2004, ISSN: 0005895040 * |
| RESPIRATORY MEDICINE, vol. Vol. 160, 2019, 105819, JPN6026027144, November 2019 (2019-11-01), ISSN: 0005895037 * |
| SCIENCE, vol. Vol. 293,No. 5532,p.1136-1138, JPN6026027143, 2001, ISSN: 0005895036 * |
| THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. Vol. 180,No. 6,p.2101-2111, JPN6026027148, 1994, ISSN: 0005895041 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240417443A1 (en) | 2024-12-19 |
| MX2024003250A (es) | 2024-05-28 |
| CN118251407A (zh) | 2024-06-25 |
| EP4405383A4 (en) | 2025-08-20 |
| KR20240069766A (ko) | 2024-05-20 |
| CA3232203A1 (en) | 2023-03-30 |
| WO2023049803A1 (en) | 2023-03-30 |
| CN119661725A (zh) | 2025-03-21 |
| EP4405383A1 (en) | 2024-07-31 |
| AU2022349077A1 (en) | 2024-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6499245B2 (ja) | 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt) | |
| CN111836827B (zh) | 包含nkg2d结构域的多特异性嵌合受体和其使用方法 | |
| CN107074929B (zh) | 嵌合自身抗体受体t细胞的组合物和方法 | |
| JP2024518011A (ja) | 多様な免疫細胞のための単鎖および多鎖合成抗原受容体 | |
| EP3025719B1 (en) | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases | |
| CN112771154B (zh) | 含有nef的t细胞及其产生方法 | |
| EP3577134A1 (en) | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities | |
| CN110511912B (zh) | 免疫细胞的功能调节 | |
| WO2020018708A1 (en) | Compositions and methods for treatment of t cell malignancies | |
| WO2021030153A2 (en) | Engineered t cell receptors and uses thereof | |
| JP2021536245A (ja) | 血液中または濃縮pbmc中のリンパ球を遺伝子改変するための方法および組成物 | |
| CN111440813A (zh) | 基于合成生物学的新型adcc技术 | |
| WO2022098750A1 (en) | Hla class ii-restricted tcrs against the kras g12>v activating mutation | |
| US20250297022A1 (en) | Engineered switches for immune cell activity and methods of use thereof | |
| WO2020018691A1 (en) | Modified t cells and methods of their use | |
| WO2018111340A1 (en) | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells | |
| EP4041410A2 (en) | Engineered trimeric cd70 proteins and uses thereof | |
| CN117202921A (zh) | 用于多种免疫细胞的单链和多链合成抗原受体 | |
| US20240417443A1 (en) | Il5ra cell surface markers | |
| CN118679261A (zh) | 经修饰的细胞及其用途 | |
| KR20240034205A (ko) | 항EGFRviii 항체, 폴리펩타이드, 상기 폴리펩타이드를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법 및 상기 폴리펩타이드를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터 | |
| US20250319130A1 (en) | Recombinant receptors binding b cell activation factor receptor and uses thereof | |
| WO2025207642A1 (en) | Cxcr3 isoforms to improve recombinant receptor trafficking | |
| WO2025212536A1 (en) | Therapeutic antibody epitope-tagged car t cells for enhanced control and safety | |
| KR20240035506A (ko) | 키메라 항원 수용체, 상기 수용체를 발현하는 세포, 상기 세포를 포함하는 의약 조성물, 상기 세포의 제조 방법, 및 상기 키메라 항원 수용체를 코딩하는 염기서열을 포함하는 폴리뉴클레오티드 또는 벡터 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250919 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250919 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260626 |